Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
Background and Aims We previously reported the comparable efficacy of bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) to that of sorafenib chemotherapy for the treatment of advanced hepatocellular carcinoma (aHCC) in patients with compensated cirrhosis. In this study, we demonstrate the e...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2019-12-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2019-0037.pdf |
| _version_ | 1828379918236385280 |
|---|---|
| author | Kei Moriya Tadashi Namisaki Shinya Sato Masanori Furukawa Akitoshi Douhara Hideto Kawaratani Kosuke Kaji Naotaka Shimozato Yasuhiko Sawada Soichiro Saikawa Hiroaki Takaya Koh Kitagawa Takemi Akahane Akira Mitoro Junichi Yamao Hitoshi Yoshiji |
| author_facet | Kei Moriya Tadashi Namisaki Shinya Sato Masanori Furukawa Akitoshi Douhara Hideto Kawaratani Kosuke Kaji Naotaka Shimozato Yasuhiko Sawada Soichiro Saikawa Hiroaki Takaya Koh Kitagawa Takemi Akahane Akira Mitoro Junichi Yamao Hitoshi Yoshiji |
| author_sort | Kei Moriya |
| collection | DOAJ |
| description | Background and Aims We previously reported the comparable efficacy of bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) to that of sorafenib chemotherapy for the treatment of advanced hepatocellular carcinoma (aHCC) in patients with compensated cirrhosis. In this study, we demonstrate the efficacy of B-HAIC in patients with decompensated cirrhosis. Methods Forty-five patients with aHCC refractory to transcatheter arterial chemo-embolization (TACE) were treated with B-HAIC and were divided into two groups according to hepatic functional reserve (Child-Pugh grade). Overall survival period, treatment response, and adverse events in each group were analyzed. Results Efficacy and disease control rates in the Child-Pugh B group (n=24; 21% and 71%, respectively) were not significantly impaired compared the Child-Pugh A group (n=21; 38% and 67%, respectively). Median survival time and survival rate at 12 months in the Child-Pugh B group were 422 days and 58.3%, respectively, whereas those in the Child-Pugh A group were 567 days and 70.8%, respectively. Importantly, the hepatic functional reserve of patients did not worsen in either group during the treatment period. Furthermore, the occurrence rate of adverse events leading to discontinuation of anti-tumor treatment was not significantly increased in the Child-Pugh B group. Conclusions Given the preservation of hepatic functional reserve afforded by B-HAIC chemotherapy in patients with decompensated cirrhosis, B-HAIC might be an acceptable alternative strategy for aHCC patients who do not respond to TACE. |
| first_indexed | 2024-12-10T03:48:10Z |
| format | Article |
| id | doaj.art-ad19b64c08394c6998198ca2faa38446 |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-12-10T03:48:10Z |
| publishDate | 2019-12-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-ad19b64c08394c6998198ca2faa384462022-12-22T02:03:21ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2019-12-0125438138910.3350/cmh.2019.00371478Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patientsKei Moriya0Tadashi Namisaki1Shinya Sato2Masanori Furukawa3Akitoshi Douhara4Hideto Kawaratani5Kosuke Kaji6Naotaka Shimozato7Yasuhiko Sawada8Soichiro Saikawa9Hiroaki Takaya10Koh Kitagawa11Takemi Akahane12Akira Mitoro13Junichi Yamao14Hitoshi Yoshiji15 Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan Department of Endoscopy, Nara Medical University, Kashihara, Japan Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Kashihara, JapanBackground and Aims We previously reported the comparable efficacy of bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) to that of sorafenib chemotherapy for the treatment of advanced hepatocellular carcinoma (aHCC) in patients with compensated cirrhosis. In this study, we demonstrate the efficacy of B-HAIC in patients with decompensated cirrhosis. Methods Forty-five patients with aHCC refractory to transcatheter arterial chemo-embolization (TACE) were treated with B-HAIC and were divided into two groups according to hepatic functional reserve (Child-Pugh grade). Overall survival period, treatment response, and adverse events in each group were analyzed. Results Efficacy and disease control rates in the Child-Pugh B group (n=24; 21% and 71%, respectively) were not significantly impaired compared the Child-Pugh A group (n=21; 38% and 67%, respectively). Median survival time and survival rate at 12 months in the Child-Pugh B group were 422 days and 58.3%, respectively, whereas those in the Child-Pugh A group were 567 days and 70.8%, respectively. Importantly, the hepatic functional reserve of patients did not worsen in either group during the treatment period. Furthermore, the occurrence rate of adverse events leading to discontinuation of anti-tumor treatment was not significantly increased in the Child-Pugh B group. Conclusions Given the preservation of hepatic functional reserve afforded by B-HAIC chemotherapy in patients with decompensated cirrhosis, B-HAIC might be an acceptable alternative strategy for aHCC patients who do not respond to TACE.http://e-cmh.org/upload/pdf/cmh-2019-0037.pdfcarcinoma, hepatocellularliver cirrhosiscisplatindrug therapydecompensated cirrhosis |
| spellingShingle | Kei Moriya Tadashi Namisaki Shinya Sato Masanori Furukawa Akitoshi Douhara Hideto Kawaratani Kosuke Kaji Naotaka Shimozato Yasuhiko Sawada Soichiro Saikawa Hiroaki Takaya Koh Kitagawa Takemi Akahane Akira Mitoro Junichi Yamao Hitoshi Yoshiji Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients Clinical and Molecular Hepatology carcinoma, hepatocellular liver cirrhosis cisplatin drug therapy decompensated cirrhosis |
| title | Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients |
| title_full | Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients |
| title_fullStr | Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients |
| title_full_unstemmed | Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients |
| title_short | Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients |
| title_sort | bi monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients |
| topic | carcinoma, hepatocellular liver cirrhosis cisplatin drug therapy decompensated cirrhosis |
| url | http://e-cmh.org/upload/pdf/cmh-2019-0037.pdf |
| work_keys_str_mv | AT keimoriya bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT tadashinamisaki bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT shinyasato bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT masanorifurukawa bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT akitoshidouhara bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT hidetokawaratani bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT kosukekaji bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT naotakashimozato bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT yasuhikosawada bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT soichirosaikawa bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT hiroakitakaya bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT kohkitagawa bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT takemiakahane bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT akiramitoro bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT junichiyamao bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients AT hitoshiyoshiji bimonthlyhepaticarterialinfusionchemotherapyasanovelstrategyforadvancedhepatocellularcarcinomaindecompensatedcirrhoticpatients |